Company Encyclopedia
View More
name
AIM VACCINE
06660.HK
AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.
1.231 T
06660.HKMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking30/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-7.91%D
    • Profit Margin-21.31%D
    • Gross Margin66.30%A
  • Growth ScoreC
    • Revenue YoY6.78%C
    • Net Profit YoY77.35%A
    • Total Assets YoY0.00%C
    • Net Assets YoY-3.58%D
  • Cash ScoreD
    • Cash Flow Margin-469.17%E
    • OCF YoY6.78%C
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreC
    • Gearing Ratio50.69%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AIM Vaccine Co. Ltd. Reports 4.2% Decline in Revenue for H1 2025 Compared to 2024

    AIM Vaccine Co., Ltd. reported a 4.2% decline in revenue for H1 2025, totaling approximately RMB514.7 million compared to RMB537.2 million in H1 2024. The decrease was primarily due to lower sales of Class II vaccines, which fell from RMB483.1 million to RMB458.8 million. Conversely, Class I vaccine sales increased from RMB54.1 million to RMB55.9 million. The company is focused on enhancing its research and development and optimizing sales efficiency through a centralized marketing model.

    Reuters·
    HK
    06660
    -2.42%
    Reuters·
    HK
    06660
    -2.42%

    Understanding the Market | AIM VACCINE surged over 6% during intraday trading, with institutions expecting the company to launch more than 10 blockbuster products in the coming years

    AIM VACCINE's stock price rose over 6% during the trading session, and as of the time of writing, it is up 4.71%, priced at HKD 4, with a trading volume of HKD 8.0917 million. In terms of news, on May 19, AIM VACCINE announced that its mRNA shingles vaccine, after receiving approval from the U.S. FDA to conduct clinical trials in March 2025, has recently obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, with approvals granted in both China and the U.S. Preclinical trial data shows that AIM VACCINE's mRNA shingles vaccine demonstrates significant advantages in key immune indicators. Fosun International Securities previously released a research report stating that AIM VACCINE has successfully commercialized 8 vaccines, including the market-leading rabies vaccine and hepatitis B vaccine, with a sales network covering the entire country and expanding overseas. More importantly, the company has a rich pipeline of 21 vaccines under research, covering five major technology platforms, with over 10 major products expected to be launched between 2025 and 2028. Among them, three key products: PCV13, the iterative acellular rabies vaccine, and PPSV23 have entered the final stages before market launch, and will be successively launched in the next 1-2 years, driving the company's performance to achieve leapfrog growth and value reassessment

    Zhitong·
    HK
    06660
    -2.42%
    Zhitong·
    HK
    06660
    -2.42%

    AIM Vaccine Co. Ltd. Announces Changes in Joint Company Secretary, Authorised Representative, and Process Agent

    AIM Vaccine Co. Ltd. has announced the resignation of Ms. Lam Wing Chi from her positions as joint company secretary, authorized representative, and process agent, effective June 13, 2025, due to work arrangement changes. The company is currently in the process of appointing her successors.

    Reuters·
    HK
    06660
    -2.42%
    Reuters·
    HK
    06660
    -2.42%

    Hong Kong pharmaceutical stocks rose against the trend, with SIHUAN PHARM up nearly 7%

    As of the time of writing, SIHUAN PHARM rose by 6.74%, Dongyangguang Changjiang Pharmaceutical rose by 5.07%, AIM VACCINE rose by 3.20%, and KINTOR PHARMA-B rose by 2.14%

    Zhitong·
    HK
    00460
    -0.81%
    HK
    06660
    -2.42%
    HK
    09939
    -3.41%
    Zhitong·
    HK
    00460
    -0.81%
    HK
    06660
    -2.42%
    HK
    09939
    -3.41%

    Top 10 HK Stock Gainers (5.22)

    STARPLUS LEGEND(06683) rose 26.25%, with a trading turnover 441.5 Million HKD, and a year-to-date rose 28%. IMMUNEONCO-B(01541) rose 17.8%, with a trading turnover 160.0 Million HKD, and a year-to-date rose 87.2%. CHINA BEST(00370) rose 15.17%, with a trading turnover 18.5 Million HKD, and a year-to-date rose 568%.

    LB Select·
    HK
    06683
    -0.99%
    HK
    01541
    -3.73%
    HK
    00370
    -1.05%
    LB Select·
    HK
    06683
    -0.99%
    HK
    01541
    -3.73%
    HK
    00370
    -1.05%
    © 2025 Longbridge｜Disclaimer